Virus-Immunotherapy combo targets Hard-to-Treat cancers
Disease control
Completed
This early-phase study tested a new treatment called NG-350A, a virus designed to activate immune cells inside tumors, combined with the immunotherapy drug pembrolizumab. It involved 14 people with advanced epithelial cancers that had stopped responding to standard treatments. Th…
Phase: PHASE1 • Sponsor: Akamis Bio • Aim: Disease control
Last updated May 17, 2026 07:52 UTC